IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein

Leukemia. 1995 Mar;9(3):419-24.

Abstract

Cell lines of myeloid origin have been shown to express interleukin-2 receptors (IL-2R). Here, we demonstrate the expression of IL-2R alpha and IL-R beta on the CML blast cell line K562 by FACS analysis and cross-linking assay. Furthermore, we examined the effect of IL-2 on leukemic progenitor growth, employing K562 as a model. Clonogenic growth was assessed after 3 days of culture by colony formation in a serum-free, semi-solid assay system. IL-2 was found to exhibit a dose-dependent suppressive effect on K562 clonogenicity with 48% inhibition of colony formation at 250 U IL-2 and 60% inhibition at 1000 U IL-2. Philadelphia chromosome (Ph)-positive K562 cells possess multiple copies of the bcr/abl fusion gene whose transcript and protein product (p210) is thought to confer growth advantage to CML cells. We therefore investigated IL-2-dependent modulation of bcr/abl mRNA accumulation and p210 protein levels in K562 cells. After 4 h of culture in the presence of IL-2, a 3-15-fold reduction of bcr/abl mRNA accumulation was demonstrated by competitive reverse PCR. Reduction of bcr/abl fusion protein levels was demonstrated at 24 h of IL-2-supplemented cell culture, employing p210 recognizing monoclonal antibodies (mAbs) in FACS analysis. Levels of proliferation marker Ki67 were only marginally affected. We conclude: (1) K562 cells express both IL-2R alpha and IL-R beta; (2) IL-2 inhibits clonogenic growth of K562 in a dose-dependent manner; and (3) IL-2-mediated inhibition of K562 proliferation is preceded by a reduction of bcr/abl mRNA accumulation and p210 protein levels.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Base Sequence
  • Blast Crisis / pathology*
  • Cell Division / drug effects
  • Depression, Chemical
  • Fusion Proteins, bcr-abl / biosynthesis*
  • Fusion Proteins, bcr-abl / genetics
  • Gene Expression Regulation, Leukemic / drug effects*
  • Humans
  • Interleukin-2 / pharmacology*
  • Ki-67 Antigen
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Molecular Sequence Data
  • Neoplasm Proteins / biosynthesis*
  • Neoplasm Proteins / genetics
  • Neoplastic Stem Cells / drug effects*
  • Nuclear Proteins / biosynthesis
  • Nuclear Proteins / genetics
  • RNA, Messenger / biosynthesis*
  • RNA, Neoplasm / biosynthesis*
  • Receptors, Interleukin-2 / biosynthesis
  • Receptors, Interleukin-2 / genetics
  • Tumor Cells, Cultured
  • Tumor Stem Cell Assay

Substances

  • Interleukin-2
  • Ki-67 Antigen
  • Neoplasm Proteins
  • Nuclear Proteins
  • RNA, Messenger
  • RNA, Neoplasm
  • Receptors, Interleukin-2
  • Fusion Proteins, bcr-abl